We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Ortho Presents Broad Menu of High-Performing Assays at EUROMEDLAB 2022

By LabMedica International staff writers
Posted on 11 Apr 2022
Print article
Image: Ortho’s assays are optimized to meet changing testing needs (Photo courtesy of Ortho Clinical Diagnostics)
Image: Ortho’s assays are optimized to meet changing testing needs (Photo courtesy of Ortho Clinical Diagnostics)

Ortho Clinical Diagnostics (Raritan, NJ, USA) presented its comprehensive, fully integrated and completely scalable solutions, including its broad menu of high-performing assays, at EUROMEDLAB 2022.

Ortho presented its VITROS Dashboards, a web-based system designed to provide productivity information regarding analyzers, test volumes, workload balance, HIT (Hemolysis, Icterus, Turbidity) levels, and reagent efficiency. The highlight of Ortho’s presentation at EUROMEDLAB 2022 was its VITROS COVID-19 Performance Dashboard - a web-based system designed to provide productivity information regarding Ortho analyzers, including volumes, workload balance, HIT levels, and reagent efficiency for each site within the health system. The VITROS COVID-19 Performance Dashboard is located within the Ortho Plus environment and is an extension of Ortho’s e-Connectivity Technology. e-Connectivity not only supports the delivery of timely and accurate results to patients and physicians, it also protects patient data.

With the ability to monitor antibody testing trends, users can adjust staffing and workflow according to their testing volumes. Labs can quantify the number of samples processed the first time - even when HIT interference is present, giving them the ability to spot negative trends in order to take action. With the VITROS COVID-19 Performance Dashboard, users have access to data that will give them a better understanding of the virus, including its impact on their lab and hospital, to adjust accordingly. With signal to cut off values, labs can see the separation between positive and negative results, giving them confidence in their results. The VITROS COVID-19 Performance Dashboard assisting users in their quest to improve laboratory efficiency and decision support while providing the best care for their patients and staff.

IN Addition, Ortho demonstrated how laboratories can contribute to patient blood management initiatives by minimizing impact of common interferences amongst other challenges. The company also exhibited its broad menu of high-performing assays that are optimized to meet the changing testing needs of laboratories.

Related Links:
Ortho Clinical Diagnostics 

Gold Member
Troponin T QC
Troponin T Quality Control
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Malaria Test
STANDARD Q Malaria P.f/Pan Ag
New
Dermatophytosis Rapid Diagnostic Kit
StrongStep Dermatophytosis Diagnostic Kit

Print article

Channels

Immunology

view channel
Image: The findings were based on patients from the ADAURA clinical trial of the targeted therapy osimertinib for patients with NSCLC with EGFR-activated mutations (Photo courtesy of YSM Multimedia Team)

Post-Treatment Blood Test Could Inform Future Cancer Therapy Decisions

In the ongoing advancement of personalized medicine, a new study has provided evidence supporting the use of a tool that detects cancer-derived molecules in the blood of lung cancer patients years after... Read more

Microbiology

view channel
Image: Schematic representation illustrating the key findings of the study (Photo courtesy of UNIST)

Breakthrough Diagnostic Technology Identifies Bacterial Infections with Almost 100% Accuracy within Three Hours

Rapid and precise identification of pathogenic microbes in patient samples is essential for the effective treatment of acute infectious diseases, such as sepsis. The fluorescence in situ hybridization... Read more
Sekisui Diagnostics UK Ltd.